Oruka Therapeutics, Inc.
ORKA
$41.48
-$0.27-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 13.14% | 36.16% | 53.97% | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -8.08% | 15.81% | 32.27% | 265.53% | |
| Operating Income | 8.08% | -15.81% | -32.27% | -265.53% | |
| Income Before Tax | 11.41% | -5.78% | -10.48% | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 11.41% | -5.78% | -10.48% | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 11.41% | -5.78% | -10.48% | -196.72% | |
| EBIT | 8.08% | -15.81% | -32.27% | -265.53% | |
| EBITDA | 8.11% | -15.76% | -- | -- | |
| EPS Basic | 17.13% | 62.66% | 93.40% | 97.39% | |
| Normalized Basic EPS | 26.91% | 63.96% | 91.61% | -- | |
| EPS Diluted | 17.13% | 62.66% | 93.40% | 97.39% | |
| Normalized Diluted EPS | 26.91% | 63.96% | 91.61% | -- | |
| Average Basic Shares Outstanding | 24.46% | 193.51% | 1,216.32% | -- | |
| Average Diluted Shares Outstanding | 24.46% | 193.51% | 1,216.32% | 8,836.45% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |